SIC-19

SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib (HY-10162) ), as well as in ovarian cancer organoids and xenograft models[1].

Product Specifications

CAS Number

[713112-69-7]

UNSPSC

12352005

Target

Salt-inducible Kinase (SIK)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sic-19.html

Purity

98.0

Solubility

DMSO : 2.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=C(C(NNC(NC(C2=CC=CC=C2)=O)=S)=O)C(C3=CC=C(OC)C(OC)=C3)=C(C)S1)C4=CC=CC=C4

Molecular Formula

C29H26N4O5S2

Molecular Weight

574.67

References & Citations

[1]Wang F, et al. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resist Updat. 2024 May;74:101077.